FORM 5

QUARTERLY LISTING STATEMENT

Name of Listed Issuer: Wellteq Digital Health Inc. (the "Issuer").

Trading Symbol: WTEQ

This Quarterly Listing Statement must be posted on or before the day on which the Issuer's unaudited interim financial statements are to be filed under the *Securities* Act, or, if no interim statements are required to be filed for the quarter, within 60 days of the end of the Issuer's first, second and third fiscal quarters. This statement is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the Exchange Policies. If material information became known and was reported during the preceding quarter to which this statement relates, management is encouraged to also make reference in this statement to the material information, the news release date and the posting date on the Exchange website.

General Instructions

(a) Prepare this Quarterly Listing Statement using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer.

(b) The term "Issuer" includes the Listed Issuer and any of its subsidiaries.

(c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

There are three schedules which must be attached to this report as follows:

SCHEDULE A: FINANCIAL STATEMENTS

Financial statements are required as follows:

For the first, second and third financial quarters interim financial statements prepared in accordance with the requirements under Ontario securities law must be attached.

If the Issuer is exempt from filing certain interim financial statements, give the date of the exempting order.

Filed under the Issuers profile on www.sedar.com.

SCHEDULE B: SUPPLEMENTARY INFORMATION

The supplementary information set out below must be provided when not included in Schedule A.

1. Related party transactions

Provide disclosure of all transactions with a Related Person, including those previously disclosed on Form 10. Include in the disclosure the following information about the transactions with Related Persons:

(a) A description of the relationship between the transacting parties. Be as precise as possible in this description of the relationship. Terms such as affiliate, associate or related company without further clarifying details are not sufficient.
(b) A description of the transaction(s), including those for which no amount has been recorded.
(c) The recorded amount of the transactions classified by financial statement category.
(d) The amounts due to or from Related Persons and the terms and conditions relating thereto.
(e) Contractual obligations with Related Persons, separate from other contractual obligations.
(f) Contingencies involving Related Persons, separate from other contingencies.

All of the information above is included in Schedule A.

2. Summary of securities issued and options granted during the period.

Provide the following information for the period beginning on the date of the last Listing Statement (Form 2A):

(a) summary of securities issued during the period,

Date of Issue	Type of Security (common shares, convertible debentures, etc.)	Type of Issue (private placement, public offering, exercise of warrants, etc.)	Number	Price	Total Proceeds	Type of Consideration (cash, property, etc.)	Describe relationship of Person with Issuer (indicate if Related Person)	Commission Paid
None								

(b) summary of options granted during the period,

Date	Number	Name of Optionee if Related Person and relationship	Generic description of other Optionees	Exercise Price	Expiry Date	Market Price on date of Grant
None						

3. Summary of securities as at the end of the reporting period.

Provide the following information in tabular format as at the end of the reporting period:

(a) description of authorized share capital including number of shares for each class, dividend rates on preferred shares and whether or not cumulative, redemption and conversion provisions,

As at September 30, 2021, the Issuer was authorized to issue an unlimited number of common shares without par value.

(b) number and recorded value for shares issued and outstanding,

As at September 30, 2021, the Issuer had 105,989,045 common shares outstanding at a book value of $24,587,215.

(c) description of options, warrants and convertible securities outstanding, including number or amount, exercise or conversion price and expiry date, and any recorded value, and

7,540,000 options at an exercise price of $0.30 up to March 19, 2024.

2,453,172 warrants at an exercise price of $0.30 up to March 19, 2023. The warrants are exercisable into units with each unit having the same terms as the units issued in the March 19, 2021 brokered subscription receipt financing.

5,828,058 warrants at an exercise price of $0.30 up to March 23, 2022.

783,474 warrants at an exercise price of $0.60 up to March 23, 2022.

16,706,108 warrants at an exercise price of $0.45 up to March 19, 2023.

(d) number of shares in each class of shares subject to escrow or pooling agreements or any other restriction on transfer.

11,051,172 common shares are subject to escrow. As at September 30, 2021, 8,288,380 common shares remained in escrow. Refer to the interim financial statements, Note 9(f), for further details.

4. List the names of the directors and officers, with an indication of the position(s) held, as at the date this report is signed and filed.

Scott Montgomery	*Chief Executive Officer and Director*
Dr. George Gellert	*Chief Medical Officer*
Andrew Kerekes	*Chief Product Officer*
Jeames Gillett	*Chief Operating Officer*
Daniel Starbuck	*Chief Technology Officer*
Olly Bridge	*Chief Growth Officer*
Matthew Anderson	*Chief Financial Officer*
Dr. Peter Vaughn	*Chairman and Director*
Brian Leeners	*Director*
Jacqueline Yee	*Director*
Andrea Johnson	*Director*

SCHEDULE C: MANAGEMENT DISCUSSION AND ANALYSIS

Provide Interim MD&A if required by applicable securities legislation.

Filed under the Issuers profile on www.sedar.com.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Quarterly Listing Statement.

2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated November 29, 2021.

Scott Montgomery
Name of Director or Senior Officer

"Scott Montgomery"
Signature

Chief Executive Officer
Official Capacity

Issuer Details Name of Issuer Wellteq Digital Health Inc.	For Quarter Ended September 30, 2021	Date of Report YY/MM/DD 21/11/29
Issuer Address 880 – 580 Hornby Street, Vancouver, BC		
City/Province/Postal Code Vancouver, BC, V6C 3B6	Issuer Fax No. ( )	Issuer Telephone No. (604) 639-4529
Contact Name Matthew Anderson	Contact Position CFO	Contact Telephone No. (604) 639-4529
Contact Email Address mja@malaspinaconsultants.com	Web Site Address https://wellteq.co/	